See more : Via Renewables, Inc. (VIA) Income Statement Analysis – Financial Results
Complete financial analysis of Tetra Bio-Pharma Inc. (TBPMF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tetra Bio-Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MultiSensor AI Holdings, Inc. (MSAIW) Income Statement Analysis – Financial Results
- Corcel Plc (CRCL.L) Income Statement Analysis – Financial Results
- Control Bionics Limited (CBL.AX) Income Statement Analysis – Financial Results
- LCNB Corp. (LCNB) Income Statement Analysis – Financial Results
- First Citrus Bancorporation, Inc. (FCIT) Income Statement Analysis – Financial Results
Tetra Bio-Pharma Inc. (TBPMF)
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 112.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 67.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 44.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 39.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.94M | 11.65M | 6.20M | 5.96M | 2.06M | 263.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.25M | 8.77M | 7.64M | 5.66M | 4.33M | 719.17K | 473.82K | 310.23K | 153.82K | 285.96K | 377.50K | 250.98K | 298.81K | 467.53K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 603.44K | 0.00 | 106.39K | 109.71K | 40.10K | 12.09K | 115.75K | 130.80K | 8.76K | 23.20K | 48.63K | 0.00 |
| SG&A | 12.25M | 8.77M | 7.64M | 5.66M | 4.33M | 719.17K | 473.82K | 310.23K | 153.82K | 401.71K | 508.30K | 259.75K | 322.01K | 516.16K | 114.28K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 113.96K | -166.80K | 0.00 | 50.00K | 0.00 | 0.00 | 0.00 | 57.00 | 525.00 | 431.00 | 20.56K | 0.00 |
| Operating Expenses | 24.30M | 20.46M | 13.86M | 11.63M | 6.40M | 982.71K | 473.82K | 310.23K | 156.21K | 401.71K | 1.55M | 424.05K | 341.13K | 528.85K | 114.28K |
| Cost & Expenses | 24.30M | 20.46M | 13.86M | 11.70M | 6.40M | 982.71K | 473.82K | 310.23K | 156.21K | 401.71K | 1.55M | 424.05K | 341.13K | 528.85K | 114.28K |
| Interest Income | 105.03K | 98.01K | 89.77K | 113.96K | 487.00 | 55.76K | 4.13K | 225.00 | 1.89K | 3.52K | 6.04K | 341.00 | 331.00 | 7.32K | 93.00 |
| Interest Expense | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.95K | 34.39K | 27.48K | 7.20K | 7.20K | 22.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.73M | -19.91M | -13.36M | -15.20M | -6.09M | -912.70K | -415.70K | -206.11K | 1.80M | -398.19K | -1.33M | -337.36K | -308.04K | 656.08K | -114.28K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -13,528.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -24.84M | -19.94M | -13.39M | -15.20M | -6.10M | -912.70K | -415.70K | -206.11K | 1.80M | -398.19K | -1.33M | -337.36K | -308.04K | 656.08K | -114.28K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -13,535.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -27.33M | -1.21M | -860.16K | 3.73M | -597.61K | -61.45K | -8.13K | -104.12K | -1.96M | -229.17K | -445.53K | -86.16K | -32.66K | -1.16M | -20.00K |
| Income Before Tax | -52.18M | -21.15M | -14.25M | -7.85M | -6.70M | -996.97K | -594.78K | -414.13K | -2.11M | -627.35K | -1.77M | -423.52K | -340.70K | -508.28K | -134.28K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -6,990.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.24M | 5.75M | 1.42M | -3.90M | -171.48K | -52.71K | 0.00 | 0.00 | 0.00 | -72.44K | -315.30K | 86.35K | 32.76K | 1.18M | -93.00 |
| Net Income | -52.18M | -26.48M | -15.28M | -7.57M | -6.23M | -944.26K | -594.78K | -414.13K | -2.11M | -554.91K | -1.46M | -509.87K | -373.46K | -1.69M | -134.18K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -6,741.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.12 | -0.10 | -0.08 | -0.05 | -0.06 | -0.01 | -0.01 | -0.01 | -0.08 | -0.02 | -0.08 | -0.04 | -0.05 | -0.32 | -0.04 |
| EPS Diluted | -0.12 | -0.10 | -0.08 | -0.05 | -0.06 | -0.01 | -0.01 | -0.01 | -0.08 | -0.02 | -0.08 | -0.04 | -0.05 | -0.32 | -0.04 |
| Weighted Avg Shares Out | 445.70M | 258.15M | 188.24M | 145.69M | 107.80M | 64.81M | 55.47M | 28.52M | 26.25M | 23.94M | 19.07M | 11.39M | 7.91M | 5.22M | 3.08M |
| Weighted Avg Shares Out (Dil) | 445.70M | 258.15M | 188.24M | 145.69M | 107.80M | 64.81M | 55.47M | 28.52M | 26.25M | 23.94M | 19.07M | 11.39M | 7.91M | 5.22M | 3.08M |
Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 The Company approaches a significant milestone advancing from a...
Tetra Bio-Pharma reports first patient dosed in trial of QIXLEEF; results from a coronavirus study of ARDS-003 and an IND update
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced multiple clinical advancements, including the dosing of the first patient in its REBORN1 trial of QIXLEEF as a treatment for cancer pain and positive results from a study of coronavirus-infected mice treated with...
Tetra Bio-Pharma secures another C$1.5M after underwriters exercise overallotment option on C$10M financing
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1) announced that Echelon Wealth Partners Inc and a syndicate of underwriters have fully exercised the overallotment option on the company's previously announced C$10 million financing, adding an additional $1.5 million in gross proceeds. The...
Tetra Bio-Pharma proposes election of two more nominees at upcoming meeting; unveils board changes
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) said it was proposing to nominate two additional directors at its upcoming annual and special meeting of shareholders scheduled for May 28, 2021 as the company reported a raft of board changes. The board believes...
Tetra Bio-Pharma closes $10M financing to support clinical trials
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) closed its previously announced bought-deal public offering raising C$10 million. The offering consisted of 25 million units priced at $0.40 per unit and led by Echelon Wealth Partners Inc and a syndicate including Canaccord Genuity...
Tetra Bio-Pharma speeds up PLENITUDE clinical trial using its cannabis medicine QIXLEEF to treat cancer pain
Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) said it is speeding up its “revolutionary” Phase 2 clinical trial, PLENITUDE, to evaluate the safety and effectiveness of its investigational cannabis medicine QIXLEEF, for use in managing uncontrolled pain in patients with advanced cancer. ...
Tetra Bio-Pharma arranges $10 million 'bought-deal' financing
Tetra Bio-Pharma Inc. (CVE:TBP) said it has entered into an agreement with a syndicate led by Echelon Wealth Partners Inc. under which the underwriters have agreed to purchase 25 million units from the treasury of the company, at a price of...
Wall Street mixed at midday despite better than expected jobs data
12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.
Tetra Bio-Pharma announces start of REBORN1 clinical trial using QIXLEEF to treat cancer pain
Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, has announced the start of the REBORN1 clinical trial. The trial is designed to evaluate the effect of the company's inhaled proprietary drug formulation, QIXLEEF, against...
Tetra Bio-Pharma Announces Start of the REBORN1(C) Clinical Trial
First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or...
Source: https://incomestatements.info
Category: Stock Reports